



1641


# FULBRIGHT & JAWORSKI L.L.P.

A REGISTERED LIMITED LIABILITY PARTNERSHIP  
600 CONGRESS AVENUE, SUITE 2400  
AUSTIN, TEXAS 78701-3271  
WWW.FULBRIGHT.COM

STEVEN L. HIGHLANDER  
PARTNER  
SHIGHLANDER@FULBRIGHT.COM

DIRECT DIAL: (512) 536-3184  
TELEPHONE: (512) 474-5201  
FACSIMILE: (512) 536-4598

December 4, 2002

CERTIFICATE OF MAILING 37 C.F.R. 1.8	
I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Box DD, Commissioner for Patents, Washington, DC 20231, on the date below:	
December 4, 2002	
Date	Steven L. Highlander

RECEIVED

DEC 16 2002

TECH CENTER 1600/2900

BOX DD  
Commissioner for Patents  
Washington, DC 20231

RE: U.S. Patent Application No. 10/028,741 entitled "*METHOD FOR MONITORING COAGULABILITY AND HYPERCOAGULABLE STATES*" filed December 20, 2002- by Shinichiro Kurosawa and Deborah J. Stearns-Kurosawa  
Our reference: OMRF:004US


Sir :

Enclosed for filing in the above-referenced patent application is a Supplemental Information Disclosure Statement, Form PTO-1449, and references (A3-A4 and C19).

No fees are believed to be due in connection with the filing of this Supplemental Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to the enclosed materials, the Commissioner is hereby authorized to deduct said fees from Fulbright & Jaworski Deposit Account No.: 50-1212/OMRF:004US.

Please date stamp and return the enclosed postcard evidencing receipt of these materials.

Respectfully Submitted,

  
Steven L. Highlander  
Reg. No. 37,642

SLH/cas

25233103.1



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Shinichiro Kurosawa and Deborah J. Stearns-Kurosawa

Group Art Unit: 1641


Examiner: Unknown

Serial No.: 10/028,741

Atty. Dkt. No.: OMRF:004US

Filed: December 20, 2001

For: METHOD FOR MONITORING  
COAGULABILITY AND  
HYPERCOAGULABLE STATES

CERTIFICATE OF MAILING 37 C.F.R. 1.8	
I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Box DD, Commissioner for Patents, Washington, DC 20231, on the date below:	
December 4, 2002	
Date	Steven L. Highlander

**RECEIVED**  
DEC 16 2002  
TECH CENTER 1600/2900

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

**BOX DD**

Commissioner for Patents  
Washington, D.C. 20231

Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Supplemental Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 be considered by the Examiner and made of record. Copies of the listed documents required by 37 C.F.R. § 1.98(a)(2) are enclosed for the convenience of the Examiner.


In accordance with 37 C.F.R §§ 1.97(g), (h), this Supplemental Information Disclosure Statement is not to be construed as a representation that a search has been made, and is not to be

construed to be an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

The present Supplemental Information Disclosure Statement is being filed prior to the receipt of a first Official Action reflecting an examination on the merits, and hence is believed to be timely filed in accordance with 37 C.F.R. § 1.97(b). No fees are believed to be due in connection with the filing of this Supplemental Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to these materials, the Commissioner is hereby authorized to deduct said fees from Fulbright & Jaworski Deposit Account No.: 50-1212/OMRF:004US.

Applicants respectfully request that the listed documents be made of record in the present case.

Respectfully submitted,



Steven L. Highlander  
Reg. No. 37,642  
Attorney for Applicants

FULBRIGHT & JAWORSKI L.L.P.  
600 Congress Avenue, Suite 2400  
Austin, Texas 78701  
(512) 474-5201

Date: December 4, 2002

Form PTO-1449 (modified)

Atty. Docket No.  
OMRF:004US/SLHSerial No.  
10/028,741

List of Patents and Publications for Applicant's

## INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Applicant  
Shinichiro Kurosawa  
Deborah J. Stearns-KurosawaFiling Date:  
December 20, 2001Group:  
1641U.S. Patent Documents  
*See Page 1*Foreign Patent Documents  
*See Page 1*Other Art  
*See Page 1*

## U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
	A3	5,935,802	8/10/99	Stuart E. Lind	435	13	8/10/98
	A4	5,981,285	11/9/99	Wallace and Jackson	436	69	7/8/98

## Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No

## Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C19	Gu rt al., "Endotoxin and thrombin elevate rodent endothelial cell protein c receptor mRNA levels and increase receptor shedding in vivo," Abstract, <i>Blood</i> , 95:1687-1693, 2000.

**RECEIVED**  
**DEC 16 2002**  
**TECH CENTER 1600/2900**

25236268.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)